Patent Grant
12251110
The present technology relates to systems, devices, and methods for treating intracranial aneurysms.
An intracranial aneurysm is a portion of an intracranial blood vessel that bulges outward from the blood vessel's main channel. This condition often occurs at a portion of a blood vessel that is abnormally weak because of a congenital anomaly, trauma, high blood pressure, or for another reason. Once an intracranial aneurysm forms, there is a significant risk that the aneurysm will eventually rupture and cause a medical emergency with a high risk of mortality due to hemorrhaging. When an unruptured intracranial aneurysm is detected or when a patient survives an initial rupture of an intracranial aneurysm, vascular surgery is often indicated. One conventional type of vascular surgery for treating an intracranial aneurysm includes using a microcatheter to dispose a platinum coil within an interior volume of the aneurysm. Over time, the presence of the coil should induce formation of a thrombus. Ideally, the aneurysm's neck closes at the site of the thrombus and is replaced with new endothelial tissue. Blood then bypasses the aneurysm, thereby reducing the risk of aneurysm rupture (or re-rupture) and associated hemorrhaging. Unfortunately, long-term recanalization (i.e., restoration of blood flow to the interior volume of the aneurysm) after this type of vascular surgery occurs in a number of cases, especially for intracranial aneurysms with relatively wide necks and/or relatively large interior volumes.
Another conventional type of vascular surgery for treating an intracranial aneurysm includes deploying a flow diverter within the associated intracranial blood vessel. The flow diverter is often a mesh tube that causes blood to preferentially flow along a main channel of the blood vessel while blood within the aneurysm stagnates. The stagnant blood within the aneurysm should eventually form a thrombus that leads to closure of the aneurysm's neck and to growth of new endothelial tissue, as with the platinum coil treatment. One significant drawback of flow diverters is that it may take weeks or months to form aneurysmal thrombus and significantly longer for the aneurysm neck to be covered with endothelial cells for full effect. This delay may be unacceptable when risk of aneurysm rupture (or re-rupture) is high. Moreover, flow diverters typically require antiplatelet therapy to prevent a thrombus from forming within the main channel of the blood vessel at the site of the flow diverter. Antiplatelet therapy may be contraindicated shortly after an initial aneurysm rupture has occurred because risk of re-rupture at this time is high and antiplatelet therapy tends to exacerbate intracranial hemorrhaging if re-rupture occurs. For these and other reasons, there is a need for innovation in the treatment of intracranial aneurysms. Given the severity of this condition, innovation in this field has immediate life-saving potential.
The present technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the present technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the present technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause. The other clauses can be presented in a similar manner.
Additional features and advantages of the present technology are described below, and in part will be apparent from the description, or may be learned by practice of the present technology. The advantages of the present technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.
Methods for treating intracranial aneurysms in accordance with at least some embodiments of the present technology include positioning an expandable occlusive member within the aneurysm and introducing an embolic element between the occlusive member and an aneurysm wall. Introduction of the embolic element both fills space within the aneurysm cavity and deforms the occlusive member from a first expanded state to a second expanded state to fortify the occlusive member at the neck of the aneurysm. Deformation of the occlusive member from a first expanded state to a second expanded state provides the additional advantage of giving visual confirmation to the physician that the delivered amount of embolic element sufficiently fills the aneurysm cavity. In addition to providing a structural support and anchor for the embolic element, the occlusive member provides a scaffold for tissue remodeling and diverts blood flow from the aneurysm. Moreover, the embolic element exerts a substantially uniform pressure on the occlusive member towards the neck of the aneurysm, thereby pressing the portions of the occlusive member positioned adjacent the neck against the inner surface of the aneurysm wall such that the occlusive member forms a complete and stable seal at the neck.
Once the occlusive member has deployed within the aneurysm and the embolic element has been delivered, the occlusive member may be detached from the delivery assembly. Suitable detachment mechanisms must be as small as possible so as to be guided through the fine bore of the catheter to the treatment site, while on the other hand they must securely and reliably produce detachment of the intrasaccular implant. Absent a reliable detachment of the intrasaccular implant, withdrawal of the delivery conduit and catheter may cause unintended removal of the occlusive member from the cavity to be occluded and thus injure and/or rupture of the wall of the cavity or vessel. In some embodiments, an electrolytic detachment mechanism as described herein can be used to facilitate reliable, controlled detachment of the occlusive member.
The occlusive member can be implanted in body cavities or blood vessels. In addition to the occlusive member, the treatment system can comprise a voltage source, a cathode, a delivery conduit, and a catheter. The occlusive member and the delivery conduit can be coupled together such that both can be slid in the catheter in the longitudinal direction. For example, the occlusive member can be coupled to a distal portion of the conduit, and the conduit can include a detachment zone configured to be electrolytically severed. In some embodiments, the conduit can be adapted to serve as an anode, such that a portion of the conduit is designed to be electrolytically corroded at one or more points so that while in contact with a body fluid, and the occlusive member may be released from the conduit. The delivery conduit can be configured to pass one or more embolic elements therethrough for intrasaccular delivery. The embolic element may be passed through the conduit and delivered to the treatment site. Once the occlusive member and any embolic elements are deployed, current can be applied to the conduit to electrolytically corrode the conduit at the detachment zone. After the conduit has been severed at the detachment zone, the conduit can be retracted, and the occlusive member may remain in position at the treatment site. In some embodiments, an inner liner and/or an outer sheath extend along at least a portion of the length of the conduit. The outer sheath can include a gap or opening that is aligned with the detachment zone such that the detachment zone of the conduit is exposed to bodily fluids while at the treatment site.
Specific details of systems, devices, and methods for treating intracranial aneurysms in accordance with embodiments of the present technology are described herein with reference to
As shown in
According to some embodiments, the second elongated shaft 108 is generally constructed to track over a conventional guidewire in the cervical anatomy and into the cerebral vessels associated with the brain and may also be chosen according to several standard designs that are generally available. Accordingly, the second elongated shaft 108 can have a length that is at least 125 cm long, and more particularly may be between about 125 cm and about 175 cm long. In some embodiments, the second elongated shaft 108 may have an inner diameter of about 0.015 inches (0.0381 cm), 0.017 inches (0.043 cm), about 0.021 inches (0.053 cm), or about 0.027 inches (0.069 cm). Other designs and dimensions are contemplated.
The elongated member 106 can be movable within the first and/or second elongated shafts 109, 108 to position the occlusive member 102 at a desired location. The elongated member 106 can be sufficiently flexible to allow manipulation, e.g., advancement and/or retraction, of the occlusive member 102 through tortuous passages. Tortuous passages can include, for example, catheter lumens, microcatheter lumens, blood vessels, urinary tracts, biliary tracts, and airways. The elongated member 106 can be formed of any material and in any dimensions suitable for the task(s) for which the system is to be employed. In some embodiments, the elongated member 106 can comprise an elongated tubular member having a lumen therein, for example a conduit. In some embodiments, the elongated member 106 may comprise any other suitable form such as a solid metal wire, an elongated tubular shaft, or any combination thereof.
In some embodiments, the elongated member 106 can comprise stainless steel, nitinol, or other metal or alloy. In some embodiments, the elongated member 106 can be surrounded over some or all of its length by a coating, such as, for example, polytetrafluoroethylene. In some examples, the elongated member 106 can be a hypotube or other conductive tubular member, and can include an outer insulative sheath and/or an inner insulative liner extending along a length of the elongated member 106. The elongated member 106 may have a diameter that is generally constant along its length, or the elongated member 106 may have a diameter that tapers radially inwardly, along at least a portion of its length, as it extends in a distal direction.
A power supply 113 may be coupled to a proximal portion of the elongated shaft 108, which can take the form of a conductive wire. The power supply 113 may also be coupled to a proximal portion of a handle or to the patient. A current can flow from the power supply 113, to a detachment zone at or near the occlusive member 102, and to a return path via the first elongated shaft 109, the second elongated shaft 108, and/or another structure extending near the detachment zone. Alternatively, the current from the detachment zone may flow to the patient, and subsequently to ground or to the power supply 113. Power supply 113, for example, may be a direct current power supply, an alternating current power supply, or a power supply switchable between a direct current and an alternating current. A positive terminal of a direct current power supply, as shown in
According to some embodiments, the occlusive member 102 may comprise a mesh 101 formed of a plurality of braided filaments that have been heat-set to assume a predetermined shape enclosing an interior volume 130 when the mesh 101 is in an expanded, unconstrained state. Example shapes include a globular shape, such as a sphere, a prolate spheroid, an oblate spheroid, and others. As depicted in
In some embodiments, the inner and outer layers 122, 124 have their distal ends fixed relative to one another at a distal coupler and meet proximally at a proximal fold surrounding an aperture. In any case, in some embodiments the conduit 116 may be configured to be slidably positioned through some or all of the second coupler 114, the interior volume 130 of the expanded mesh 101, and the opening 126.
The inner and outer layers 122 and 124 may conform to one another at the distal portion (for example as shown in
The inner layer 124 may have a shape that substantially conforms to the shape of the outer layer 124, or the inner and outer layers 122, 124 may have different shapes. For example, as shown in
In any case, both the proximal portion and the distal portion of the mesh 101 can form generally closed surfaces. However, unlike at the proximal portion of the mesh 101, the portion of the filaments at or near the fold 128 at the distal portion of the mesh 101 can move relative to one another. As such, the distal portion of the mesh 101 has both the properties of a closed end and also some properties of an open end (like a traditional stent), such as some freedom of movement of the distal-most portions of the filaments and an opening through which the conduit 116, a guidewire, guidetube, or other elongated member may pass through.
In some embodiments, each of the plurality of filaments have a first end positioned at the proximal portion of the mesh 101 and a second end also positioned at the proximal portion of the mesh 101. Each of the filaments may extend from its corresponding first end distally along the body of the mesh 101 to the fold 128, invert, then extend proximally along the mesh body to its corresponding second end at the proximal portion of the mesh 101. As such, each of the plurality of filaments have a first length that forms the inner layer 122 of the mesh 101, a second length that forms the outer layer 124 of the mesh 101, and both first and second ends fixed at the proximal portion of the mesh 101. In some embodiments, the occlusive member 102 may comprise a mesh formed of a single layer, or a mesh formed of three or more layers.
In some embodiments, the distal end surface of the mesh 101 is completely closed (i.e., does not include an aperture). In some embodiments the filaments are fixed relative to the at both the proximal and distal ends of the occlusive member 102.
The mesh 101 may be formed of metal wires, polymer wires, or both, and the wires may have shape memory and/or superelastic properties. The mesh 101 may be formed of 24, 32, 36, 48, 64, 72, 96, 128, or 144 filaments. The mesh 101 may be formed of a range of filament or wire sizes, such as wires having a diameter of from about 0.0004 inches to about 0.0020 inches, or of from about 0.0009 inches to about 0.0012 inches. In some embodiments, each of the wires or filaments have a diameter of about 0.0004 inches, about 0.0005 inches, about 0.0006 inches, about 0.0007 inches, about 0.0008 inches, about 0.0009 inches, about 0.001 inches, about 0.0011 inches, about 0.0012 inches, about 0.0013 inches, about 0.0014 inches, about 0.0015 inches, about 0.0016 inches, about 0.0017 inches, about 0.0018 inches, about 0.0019 inches, or about 0.0020 inches. In some embodiments, all of the filaments of the braided mesh 101 may have the same diameter. For example, in some embodiments, all of the filaments have a diameter of about 0.001 inches. In some embodiments, some of the filaments may have different cross-sectional diameters. For example, some of the filaments may have a slightly thicker diameter to impart additional strength to the braided layers. In some embodiments, some of the filaments can have a diameter of about 0.001 inches, and some of the filaments can have a diameter of greater than 0.001 inches. The thicker filaments may impart greater strength to the braid without significantly increasing the device delivery profile, with the thinner wires offering some strength while filling-out the braid matrix density.
The occlusive member 102 can have different shapes and sizes in an expanded, unconstrained state. For example, the occlusive member 102 may have a bullet shape, a barrel-shape, an egg shape, a dreidel shape, a bowl shape, a disc shape, a cylindrical or substantially cylindrical shape, a barrel shape, a chalice shape, etc.
The embolic kit 200 may include one or more precursors for creation of a liquid embolic. For example, the embolic kit 200 may include a first container 202 containing a first precursor material 203 (shown schematically), a second container 204 containing a second precursor material 205 (also shown schematically), and a mixing device 206 suitable for mixing the first and second precursor materials 203, 205. The mixing device 206 can include mixing syringes 208 (individually identified as mixing syringes 208a, 208b) and a coupler 210 extending between respective exit ports (not shown) of the mixing syringes 208. The mixing syringes 208a, 208b each include a plunger 212 and a barrel 214 in which the plunger 212 is slidably received.
The embolic kit 200 can further include an injection syringe 216 configured to receive a mixture of the first and second precursor materials 203, 205 and deliver the mixture to a proximal portion 100b of the treatment assembly 100. The injection syringe 216 can include a barrel 220, an exit port 222 at one end of the barrel 220, and a plunger 224 slidably received within the barrel 220 via an opposite end of the barrel 220. The handle 103 of the treatment system 100 may have a coupler configured to form a secure fluidic connection between the lumen and the exit port 222 of the injection syringe 216.
The first and second precursor materials 203, 205 can include a biopolymer and a chemical crosslinking agent, respectively. The chemical crosslinking agent can be selected to form covalent crosslinks between chains of the biopolymer. In some embodiments, the biopolymer of the first precursor material 203 includes chitosan or a derivative or analog thereof, and the chemical crosslinking agent of the second precursor material 205 includes genipin or a derivative or analog thereof. Other suitable crosslinking agents for use with chitosan include glutaraldehyde, functionalized polyethylene glycol, and derivatives and analogs thereof. In other embodiments, the biopolymer of the first precursor material 203 can include collagen or a derivative or analog thereof, and the chemical crosslinking agent of the second precursor material 205 can include hexamethylene diisocyanate or a derivative or analog thereof. Alternatively or in addition, genipin or a derivative or analog thereof can be used as a chemical crosslinking agent for a collagen-based biopolymer. In still other embodiments, the biopolymer of the first precursor material 203 and the chemical crosslinking agent of the second precursor material 205 can include other suitable compounds alone or in combination.
Mixing the biopolymer of the first precursor material 203 and the chemical crosslinking agent of the second precursor material 205 can initiate chemical crosslinking of the biopolymer. After the first and second precursor materials 203, 205 are mixed, chemical crosslinking of the biopolymer occurs for enough time to allow the resulting embolic element 230 be delivered to the aneurysm before becoming too viscous to move through the lumen of the conduit 116. In addition, the period of time during which chemical crosslinking of the biopolymer occurs can be short enough to reach a target deployed viscosity within a reasonable time (e.g., in the range of 10-60 minutes; or at most 40 minutes, 30 minutes, 20 minutes, or 10 minutes) after delivery. The target deployed viscosity can be high enough to cause an agglomeration of the embolic element 230 to remain within the internal volume of the aneurysm without reinforcing the neck.
In at least some cases, the biopolymer has a non-zero degree of chemical crosslinking within the first precursor material 203 before mixing with the chemical crosslinking agent. This can be useful, for example, to customize the curing window for the embolic element 230 so that it corresponds well with an expected amount of time needed to deliver the material to the aneurysm. The degree of chemical crosslinking of the biopolymer within the first precursor material 203 before mixing with the chemical crosslinking agent, the ratio of the biopolymer to the chemical crosslinking agent, and/or one or more other variables can be selected to cause the embolic element 230 to have a viscosity suitable for delivery to the aneurysm via the lumen of the conduit 116 for a suitable period of time (e.g., a period within a range from 10 minutes to 40 minutes) after mixing of the first and second precursor materials 203, 205. In at least some cases, the first and second precursor materials 203, 205 are mixed in proportions that cause a weight ratio of the biopolymer to the chemical crosslinking agent in the resulting embolic element 230 to be within a range from 10:1 to 100:1, such as from 10:1 to 30:1, or from 15:1 to 50:1, or from 15:1 to 25:1. In a particular example, the first and second precursor materials 203, 205 are mixed in proportions that cause a weight ratio of the biopolymer to the chemical crosslinking agent in the resulting embolic element 230 to be 30:1.
Use of a biopolymer instead of an artificial polymer in the first precursor material 203 may be advantageous because biopolymers tend to be more readily bioabsorbed than artificial polymers and/or for other reasons. Furthermore, use of a chemical crosslinking agent instead of a physical crosslinking agent (i.e., a crosslinking agent that forms noncovalent crosslinks between chains of the biopolymer) in the second precursor material 205 may be advantageous because chemically crosslinked polymers tend to be more cohesive than physically crosslinked polymers and/or for other reasons. In the context of forming a tissue scaffold within an aneurysm, high cohesiveness of the embolic element 230 may be more important than it is in other contexts to secure the cured embolic element 230 within the aneurysm 302. For example, high cohesiveness of the embolic element 230 may reduce or eliminate the possibility of a piece of the embolic element 230 breaking free and entering a patient's intracerebral blood stream during delivery.
The first and second precursor materials 203, 205 may include other components and/or the kit 200 may include other precursor materials intended for mixing with the first and second precursor materials 203, 205. For example, the first, second, and/or another precursor material may include a physical crosslinking agent. The presence of a physical crosslinking agent may be useful to form physical crosslinks that complement chemical crosslinks from the chemical crosslinking agent. The combination of chemical and physical crosslinks may enhance the cohesiveness of the embolic element 230. Suitable physical crosslinking agents for use with chitosan-based biopolymers include β glycerophosphate, mannitol, glucose, and derivatives and analogs thereof. In these and other cases, the embolic element 230 may include multiple chemical crosslinking agents and/or multiple physical crosslinking agents.
A contrast agent is another component that may be added to the precursor materials. The presence of a contrast agent within the embolic element 230 can be useful to visualize delivery of the embolic element 230 using fluoroscopy. One problem with using conventional platinum coils in intracranial aneurysms is that the persistent radiopacity of the coils tends to interfere with visualizing other aspects of the treatment in follow-up imaging. For example, the presence of platinum coils within an aneurysm may make it difficult or impossible to detect by fluoroscopy the presence of blood-carried contrast agent that would otherwise indicate recanalization. In at least some embodiments of the present technology, a contrast agent within the embolic element 230 is selected to provide radiopacity that diminishes over time. For example, the contrast agent may initially be radiopaque to facilitate delivery of the embolic element 230 and then become less radiopaque to facilitate follow-up imaging. In a particular example, the first, second, and/or another precursor material includes iohexol or a derivative or analog thereof as a suitable contrast agent.
In animal studies, the liquid embolics of the present technology were shown to provide (a) complete or nearly complete volumetric filling of the aneurysm internal volume, and (b) complete or nearly complete coverage of the aneurysm neck with new endothelial tissue. These features, among others, are expected to result in a lower recanalization rate than that of platinum coil treatments and faster aneurysm occlusion than that of flow diverters. Furthermore, the injectable scaffold material is expected to be bioabsorbed and thereby reduced in volume over time. Thus, unlike platinum coils, the injectable scaffold is expected to have little or no long-term mass effect. Furthermore, the injectable scaffold material can be configured to have diminishing radiopacity; therefore, when so configured it will not interfere future CT and MRI imaging and procedures. Embodiments of the present technology can have these and/or other features and advantages relative to conventional counterparts whether or not such features and advantages are described herein.
In some embodiments, the embolic kit 200 and/or embolic element 230 may be any embolic or occlusive device, such as one or more embolic coils, polymer hydrogel(s), polymer fibers, mesh devices, or combinations thereof. The embolic kit 200 may include one or more precursors that, once mixed together, form the embolic element 230 that remains within the aneurysm. In some embodiments, the embolic kit 200 may include the embolic element pre-mixed.
In some embodiments, the embolic kit 200 and/or embolic element 230 may be any embolic or occlusive device, such as one or more embolic coils, polymer hydrogel(s), polymer fibers, mesh devices, or combinations thereof. The embolic kit 200 may include one or more precursors that, once mixed together, form the embolic element 230 that remains within the aneurysm. In some embodiments, the embolic kit 200 may include the embolic element pre-mixed.
Additional details regarding suitable embolic element may be found in U.S. patent application Ser. No. 15/299,929, filed Oct. 21, 2016, the disclosure of which is incorporated herein by reference in its entirety.
In some embodiments, the method includes mixing the first and second precursor materials 203, 205 (
Still with reference to
During and after delivery of the embolic element 230, none or substantially none of the embolic element 230 migrates through the pores of the occlusive member 102 and into the internal volume 130. Said another way, all or substantially all of the embolic element 230 remains at the exterior surface or outside of the occlusive member 102. Compression of the occlusive member with the embolic element 230 provides a real-time “leveling” or “aneurysm-filling indicator” to the physician under single plane imaging methods (such as fluoroscopy) so that the physician can confirm at what point the volume of the aneurysm is completely filled. It is beneficial to fill as much space in the aneurysm as possible, as leaving voids within the aneurysm sac may cause delayed healing and increased risk of aneurysm recanalization and/or rupture. While the scaffolding provided by the occlusive member 102 across the neck helps thrombosis of blood in any gaps and healing at the neck, the substantial filling of the cavity prevents rupture acutely and does not rely on the neck scaffold (i.e., the occlusive member 102). Confirmation of complete or substantially complete aneurysm filling under single plane imaging cannot be provided by conventional devices.
Once delivery of the embolic element 230 is complete, the conduit 116 may be withdrawn. In some embodiments, the embolic element 230 may fill greater than 40% of the aneurysm sac volume. In some embodiments, the embolic element 230 may fill greater than 50% of the aneurysm sac volume. In some embodiments, the embolic element 230 may fill greater than 60% of the aneurysm sac volume. In some embodiments, the embolic element may fill greater than 65%, 70%, 75%, 80%, 85%, or 90% of the aneurysm sac volume.
In the second expanded state, the occlusive member 102 may form a bowl shape that extends across the neck of the aneurysm A. The wall of the occlusive member 102 at the distal portion may now be positioned in contact with or immediately adjacent the wall of the occlusive member 102 at the proximal portion. The distal wall 132 may be in contact with the proximal wall 134 along all or substantially all of its length. In some embodiments, the distal wall 132 may be in contact with the proximal wall 134 along only a portion of its length, while the remainder of the length of the distal wall 132 is in close proximity—but not in contact with—the proximal wall 134.
Collapse of the occlusive member 102 onto itself, towards the neck N of the aneurysm, may be especially beneficial as it doubles the number of layers across the neck and thus increases occlusion at the neck N. For example, the distal wall 132 collapsing or inverting onto the proximal wall 134 may decrease the porosity of the occlusive member 102 at the neck N. In those embodiments where the occlusive member 102 is a mesh or braided device such that the distal wall 132 has a first porosity and the proximal wall 134 has a second porosity, deformation of the distal wall 132 onto or into close proximity within the proximal wall 134 decreases the effective porosity of the occlusive member 102 over the neck N. The resulting multi-layer structure thus has a lower porosity than the individual first and second porosities. Moreover, the embolic element 230 along the distal wall 132 provides additional occlusion. In some embodiments, the embolic element 230 completely or substantially completely occludes the pores of the adjacent layer or wall of the occlusion member 102 such that blood cannot flow past the embolic element 230 into the aneurysm cavity. It is desirable to occlude as much of the aneurysm as possible, as leaving voids of gaps can allow blood to flow in and/or pool, which may continue to stretch out the walls of aneurysm A. Dilation of the aneurysm A can lead to recanalization and/or herniation of the occlusive member 102 and/or embolic element 230 into the parent vessel and/or may cause the aneurysm A to rupture. Both conditions can be fatal to the patient.
In those embodiments where the wall of the occlusive member 102 comprises an inner and outer layer, the deformed or second shape of the occlusive member 102 forms four layers over the neck N of the aneurysm A In those embodiments where the wall of the occlusive member 102 comprises a single layer, the deformed or second shape of the occlusive member 102 forms two layers over the neck N of the aneurysm A As previously mentioned, the neck coverage provided by the doubled layers provides additional surface area for endothelial cell growth, decreases the porosity of the occlusive member 102 at the neck N (as compared to two layers or one layer), and prevents herniation of the embolic element 230 into the parent vessel. During and after delivery, the embolic element 230 exerts a substantially uniform pressure on the occlusive member 102 towards the neck N of the aneurysm A, thereby pressing the portions of the occlusive member 102 positioned adjacent the neck against the inner surface of the aneurysm wall such that the occlusive member 102 forms a complete and stable seal at the neck N.
As shown in
Over time natural vascular remodeling mechanisms and/or bioabsorption of the embolic element 230 may lead to formation of a thrombus and/or conversion of entrapped thrombus to fibrous tissue within the internal volume of the aneurysm A. These mechanisms also may lead to cell death at a wall of the aneurysm and growth of new endothelial cells between and over the filaments or struts of the occlusive member 102. Eventually, the thrombus and the cells at the wall of the aneurysm may fully degrade, leaving behind a successfully remodeled region of the blood vessel.
In some embodiments, contrast agent can be delivered during advancement of the occlusive member 102 and/or embolic element 230 in the vasculature, deployment of the occlusive member 102 and/or embolic element 230 at the aneurysm A, and/or after deployment of the occlusive member 102 and/or embolic element 230 prior to initiation of withdrawal of the delivery system. The contrast agent can be delivered through the second elongated shaft 108, the conduit 116, or through another catheter or device commonly used to delivery contrast agent. The aneurysm (and devices therein) may be imaged before, during, and/or after injection of the contrast agent, and the images may be compared to confirm a degree of occlusion of the aneurysm.
According to some aspects of the technology, the system 10 may comprise separate first and second elongated shafts (e.g., microcatheters) (not shown), the first dedicated to delivery of the embolic element, and the second dedicated to the delivery of the occlusive member. In example methods of treating an aneurysm, the first elongated shaft may be intravascularly advanced to the aneurysm and through the neck such that that a distal tip of the first elongated shaft is positioned within the aneurysm cavity. In some embodiments, the first elongated shaft may be positioned within the aneurysm cavity such that the distal tip of the shaft is near the dome of the aneurysm.
The second elongated shaft containing the occlusive member (such as occlusive member 102) may be intravascularly advanced to the aneurysm and positioned within the aneurysm cavity adjacent the first elongated shaft. The occlusive member may then be deployed within the aneurysm sac. As the occlusive member is deployed, it pushes the first elongated shaft outwardly towards the side of the aneurysm, and when fully deployed the occlusive member holds or “jails” the first elongated shaft between an outer surface of the occlusive member and the inner surface of the aneurysm wall.
The embolic element (such as embolic element 230) may then be delivered through the first elongated shaft to a position between the inner surface of the aneurysm wall and the outer surface of the occlusive member. For this reason, it may be beneficial to initially position the distal tip of the first elongated shaft near the dome (or more distal surface) of the aneurysm wall. This way, the “jailed” first elongated shaft will be secured by the occlusive member such that the embolic element gradually fills the open space in the aneurysm sac between the dome and the occlusive member. As described elsewhere herein, the filling of the embolic element pushes and compresses the occlusive member against the tissue surrounding the aneurysm neck as the space in the sac above the occlusive member is being filled from the dome to the neck. Also as described elsewhere herein, the compression of the occlusive member with the embolic element provides a “leveling or aneurysm filling indicator” which is not provided by conventional single plane imaging methods. The filling of the embolic element may complete, for example, when it occupies about 50-80% of the volume of the aneurysm.
Although several examples refer to the use of electrolytic detachment, in various embodiments other techniques can be used to sever a conduit and release the occlusive member 102. For example, instead of or in addition to electrolytic detachment, embodiments of the present technology may utilize thermal detachment, mechanical detachment, chemical detachment, or any other suitable detachment techniques.
Referring to
In various embodiments, the conduit assembly 402 can include a single tubular member or a plurality of tubular members arranged coaxially. Moreover, any one of the tubular members can be monolithic or can be formed of multiple separate components joined together. Additionally or alternatively, some or all of the tubular member(s) can include one or more coatings along some or all of their respective lengths. In some embodiments, one or more of the tubular members can be slidably moveable with respect to other tubular members. Alternatively or additionally, one or more of the tubular members can be fixed (e.g., non-slidably coupled) with respect to the other tubular members.
In the embodiment illustrated in
In various embodiments, the conduit assembly 402 can have a length sufficient to permit the occlusive member 102 to be positioned at an intravascular treatment site (e.g., within an aneurysm sac) while a proximal end of the conduit assembly 402 extends outside the patient's body. For example, the conduit assembly 402 can have a length of greater than about 50 inches, 60 inches, 70 inches, or 80 inches. The conduit assembly 402 can have an outer diameter suitable to permit the assembly 402 to be slidably advanced through a delivery catheter. For example, the conduit assembly 402 can have an outer diameter of less than about 0.027 inches, less than about 0.021 inches, or less than about 0.017 inches.
In the example shown in
As noted above, the conduit assembly 402 includes a conduit 420, which can be radially disposed between an outer sheath 430 and an inner liner 440. The conduit 420 includes a proximal portion 422, a distal portion 424, and a detachment zone 426 disposed axially between the proximal portion 422 and the distal portion 424. In some embodiments, the conduit 420 can be an electrically conductive tubular member, for example a hypotube, catheter, or other suitable tubular member. In some embodiments, a portion of the conduit 420, including the detachment zone 426, can be coated with a conductive material, such as carbon, gold, platinum, tantalum, combinations thereof, and the like. One or more metallic coatings can be applied using known plating techniques. In various embodiments, the conduit 420 can have cuts (e.g., a spiral cut, a groove, etc.) along at least a portion of its length to achieve the desired mechanical properties (e.g., column strength, flexibility, kink-resistance, etc.).
The conduit 420 can be dimensioned to facilitate intravascular advancement to the treatment site and to accommodate a lumen 404 sufficient to permit advancement of embolic element(s) therethrough. In some embodiments, the conduit 420 can have a wall thickness of between about 0.0005 inches and about 0.0015 inches, or about 0.001 inches in some examples. The conduit 420 can have an outer diameter in the proximal portion of less than about 0.027 inches, less than about 0.021 inches, or less than about 0.017 inches. Additionally or alternatively, the conduit 420 can have an inner diameter of less than about 0.015 inches, less than about 0.012 inches, less than about 0.010 inches, or less than about 0.008 inches. As shown in
The conduit 420, including the detachment zone 426, can include one or more of the following materials: ceramic materials, plastics, base metals or alloys thereof, for example stainless steel or nitinol. Some of the most suitable material combinations for forming the electrolytically corrodible points can include one or more of the following: stainless steels, preferably of the type AISI 301, 304, 316, or subgroups thereof; Ti or TiNi alloys; Co-based alloys; noble metals; or noble metal alloys, such as Pt, Pt metals, Pt alloys, Au alloys, or Sn alloys. Further, ceramic materials and plastics employed for forming the medical device can be electrically conductive.
In some embodiments, the detachment zone 426 can include features to facilitate electrolytic severability, such as features configured to reduce a time that current must be supplied to the conduit 420 before the conduit is severed at the detachment zone 426. In some embodiments, the detachment zone 426 can include a sidewall having one or more openings 428 formed therein, which can take the form of one or more windows, slits, apertures, holes, or other such features. The openings 428 can both increase the surface-area-to-volume ratio at the detachment zone 426, and can also reduce the overall amount of material forming the sidewall of the conduit 420 at the detachment zone 426. As a result, the sidewall material of the conduit 420 at the detachment zone 426 may be more readily electrolytically corroded when current is supplied to the conduit 420 and the detachment zone 426 is exposed to an electrolytic medium such as blood. Additionally or alternatively to the openings 428, the detachment zone 426 can include a reduced sidewall thickness of the conduit 420, and/or otherwise provide a lower material density than the proximal and distal portions 422, 424 of the conduit 420. In some embodiments, the detachment zone 426 can be surface treated (e.g., using laser or chemical treatment) to create a microstructure at the detachment zone 426 that differs from that of the proximal and distal portions 422, 424 of the conduit 420 to facilitate electrolytic detachment. For example, the detachment zone 426 can have a microstructure having a lower crystallinity than each of the conduit proximal portion 422 and conduit distal portion 424. As another example, the detachment zone 426 can have a microstructure that is more amorphous than each of the conduit proximal portion 422 and conduit distal portion 424.
According to some embodiments, portions of the conduit 420 can be covered with an electrically insulative material. For example, a sheath 430 that is made of or includes an electrically insulative material can extend over a radially outer surface of the conduit 420 along at least a portion of the length of the conduit 420. For example, the sheath 430 can include a proximal portion 432 that circumferentially surrounds an outer surface of the conduit proximal portion 422. The sheath 430 can also include a distal portion 434 that circumferentially surrounds an outer surface of the conduit distal portion 424. A void or gap 436 can separate the sheath proximal and distal portions 432, 434. In some embodiments, the sheath proximal and distal portions 432, 434 can be discrete members that are not connected to one another, while in other embodiments the proximal and distal portions 432, 434 may be connected across the gap 436, for example via connecting strands of material.
The sheath 430 can be fully or partially made of an electrically nonconductive or insulative polymer, such as polyimide, polypropylene, polyolefins, combinations thereof, and the like. In some embodiments, the sheath 430 takes the form of an extruded polymeric tube (e.g., PTFE), and the sheath 430 extends distally beyond the hub 406 and distally beyond a distal end of the conduit 420. Accordingly, in some embodiments, the sheath 430 can define the distal opening of the conduit assembly 402. In some embodiments, the distal end of the sheath 430 is disposed adjacent or distal to a distal end of the occlusive member 102 when the occlusive member 102 is in its expanded state. According to some embodiments, the distal end of the sheath 430 is disposed adjacent or distal to a distal end of the occlusive member 102 when the occlusive member 102 is in its low-profile state.
The sheath 430 can be dimensioned to facilitate intravascular advancement to the treatment site and to accommodate a lumen 404 sufficient to permit advancement of embolic element(s) therethrough. In some embodiments, the sheath 430 can have a wall thickness of between about 0.0005 inches and about 0.002 inches, or about 0.0015 inches in some examples. The sheath 430 can have an outer diameter in the proximal portion of less than about 0.027 inches, less than about 0.021 inches, less than about 0.017 inches, or less than about 0.015 inches. Additionally or alternatively, the sheath 430 can have an inner diameter of less than about 0.015 inches, less than about 0.012 inches, less than about 0.010 inches, or less than about 0.008 inches. As shown in
According to some embodiments, a gap 436 between the sheath proximal and distal portions 432, 434 leaves exposed the detachment zone 426 of the underlying conduit 420. When in contact with a body fluid, such as blood, the fluid serves as an electrolyte allowing current to be focused on the non-covered detachment zone 426. The sheath proximal and distal portions 422, 424 prevent exposure of the conduit proximal portion 422 and the conduit distal portion 424 to the fluid. Accordingly, electrical energy conducted along the conduit 420 is concentrated at the detachment zone 426, thereby reducing the time required to erode away the detachment zone 426. The sheath proximal and distal portions 432, 434 can be slidably disposed over, over-molded, co-extruded, sprayed on, or dip-coated with respect to the conduit 420.
The gap 436 between the sheath proximal portion 432 and the sheath distal portion 434 can be dimensioned so as to achieve the desired exposure of the underlying detachment zone 426. According to some embodiments, the gap 436 can be as small as 0.0005 inches and as large as 0.1 inches or longer. According to some embodiments, lengths of detachment zone 426 can be greater than 0.005 inches and/or less than 0.010 inches to provide sufficient exposure to achieve detachment times of less than 30 seconds.
According to some embodiments, the sheath distal portion 434 is disposed radially between the distal portion 424 of the conduit 420 and the hub 406 of the occlusive member 102. As shown in
As noted above, an inner liner 440 can be disposed radially inwardly of the conduit 420. The liner 440 can be an elongate tubular member and can be made of an electrically insulative material. In some embodiments, the liner 440 can have an inner surface defining the lumen 404 along at least a portion of the length of the conduit assembly 402. Accordingly, the inner surface of the liner 440 can be continuous and uninterrupted along its length, such that liquid embolic material passing therethrough is contained within the lumen 404 until it reaches a distal end of the liner 440. In particular, the liner 440 can provide a continuous and uninterrupted surface along the detachment zone 426 of the conduit 420, such that any embolic element(s) cannot pass from within the lumen 404 through the openings 428 in the conduit 420 at the detachment zone 426.
In various embodiments, the liner 440 can extend distally to be coterminous with the conduit 420 (e.g., at or adjacent a distal end of the hub 406), or alternatively the liner 440 can extend distally beyond the hub 406 and/or distally beyond a distal end of the conduit 420. The liner 440 can be made of or coated with a lubricious material to facilitate advancement of embolic element(s) therethrough. In some embodiments, the liner 440 takes the form of an extruded polymeric tube (e.g., PTFE) or other suitable electrically insulative material. Additionally or alternatively, the inner liner 440 can be co-extruded, sprayed on, or dip-coated with respect to the conduit 420.
The liner 440 can be dimensioned to facilitate intravascular advancement to the treatment site and to accommodate a lumen 404 sufficient to permit advancement of embolic element(s) therethrough. In some embodiments, the liner 440 can have a wall thickness of between about 0.0005 inches and about 0.0015 inches, or about 0.001 inches in some examples. The liner 440 can have an outer diameter in the proximal portion of less than about 0.027 inches, less than about 0.021 inches, or less than about 0.017 inches. Additionally or alternatively, the liner 440 can have an inner diameter of less than about 0.015 inches, less than about 0.012 inches, less than about 0.010 inches, or less than about 0.008 inches. As shown in
In some embodiments, an embolic element can be delivered through the lumen 404 of the conduit assembly 402. The lumen 404 can terminate in a distal opening (not shown). As noted above, in some embodiments, the conduit assembly 402 can include an elongate flexible tubular member, for example a catheter, hypotube, polymer tube, etc. The lumen 404 can be coated with a lubricious material or lining to facilitate advancement of embolic element(s) therethrough. In some embodiments, the conduit assembly 402 is dimensioned such that the distal opening is disposed adjacent to, completely distal of, or at least partially distal of the occlusive member 102 while the occlusive member 102 is in the unexpanded state. The conduit assembly 402 can be dimensioned and configured such that the distal opening is disposed at distal to the hub 406 of the occlusive member 102, such that embolic element(s) delivered therethrough can be delivered to a region adjacent or distal of the occlusive member 102.
In the position shown in
As shown in
As described previously with respect to
As shown in
Although many of the embodiments are described above with respect to systems and methods related to treatment of hemorrhagic stroke, the technology is applicable to other applications and/or other approaches. Moreover, other embodiments in addition to those described herein are within the scope of the technology. Additionally, several other embodiments of the technology can have different configurations, components, or procedures than those described herein. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described above with reference to
The descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Where the context permits, singular or plural terms may also include the plural or singular term, respectively. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
Unless otherwise indicated, all numbers expressing dimensions, percentages, or other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present technology. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Additionally, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a range of “1 to 10” includes any and all subranges between (and including) the minimum value of 1 and the maximum value of 10, i.e., any and all subranges having a minimum value of equal to or greater than 1 and a maximum value of equal to or less than 10, e.g., 5.5 to 10.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
The present application is a continuation of U.S. patent application Ser. No. 16/949,566, filed Nov. 3, 2020, which claims the benefit of priority of U.S. Provisional Application No. 62/930,421, filed Nov. 4, 2019, U.S. Provisional Application No. 62/930,487, filed Nov. 4, 2019, U.S. Provisional Application No. 62/930,303, filed Nov. 4, 2019, U.S. Provisional Application No. 62/930,324, filed Nov. 4, 2019, U.S. Provisional Application No. 62/930,333, filed Nov. 4, 2019, and U.S. Provisional Application No. 62/930,357, filed Nov. 4, 2019, each of which is incorporated by reference herein in its entirety. The following applications are also incorporated by reference herein in their entireties: U.S. patent application Ser. No. 16/949,567, filed Nov. 3, 2020, and titled DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS; U.S. patent application Ser. No. 16/949,568, filed Nov. 3, 2020, and titled DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS; U.S. patent application Ser. No. 16/949,561, filed Nov. 3, 2020, and titled SYSTEMS AND METHODS FOR TREATING ANEURYSMS; U.S. patent application Ser. No. 16/949,563, filed Nov. 3, 2020, and titled SYSTEMS AND METHODS FOR TREATING ANEURYSMS; U.S. patent application Ser. No. 16/949,564, filed Nov. 3, 2020, and titled SYSTEMS AND METHODS FOR TREATING ANEURYSMS; U.S. patent application Ser. No. 16/949,565, filed Nov. 3, 2020, and titled ANEURYSM TREATMENT DEVICE; U.S. patent application Ser. No. 16/949,569, filed Nov. 3, 2020, and titled DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS; U.S. patent application Ser. No. 16/949,570, filed Nov. 3, 2020, and titled DEVICES, SYSTEMS, AND METHODS FOR TREATING ANEURYSMS; and International Application No. PCT/US20/70743, filed Nov. 3, 2020, titled DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS; International Application No. PCT/US2020/070741, filed Nov. 3, 2020, titled DEVICES, SYSTEMS, AND METHODS FOR TREATMENT OF INTRACRANIAL ANEURYSMS; and International Application No. PCT/US2020/070742, filed Nov. 3, 2020, titled SYSTEMS AND METHODS FOR TREATING ANEURYSMS.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5250071 | Palermo | Oct 1993 | A |
| 5261916 | Engelson | Nov 1993 | A |
| 5284488 | Sideris | Feb 1994 | A |
| 5326350 | Li | Jul 1994 | A |
| 5354295 | Guglielmi et al. | Oct 1994 | A |
| 5405379 | Lane | Apr 1995 | A |
| 5417708 | Hall et al. | May 1995 | A |
| 5601600 | Ton | Feb 1997 | A |
| 5645558 | Horton | Jul 1997 | A |
| 5669931 | Kupiecki et al. | Sep 1997 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5733294 | Forber et al. | Mar 1998 | A |
| 5741333 | Frid | Apr 1998 | A |
| 5749891 | Ken et al. | May 1998 | A |
| 5749894 | Engelson | May 1998 | A |
| 5749895 | Sawyer et al. | May 1998 | A |
| 5749919 | Blanc | May 1998 | A |
| 5814062 | Sepetka et al. | Sep 1998 | A |
| 5823198 | Jones et al. | Oct 1998 | A |
| 5846261 | Kotula et al. | Dec 1998 | A |
| 5911731 | Pham et al. | Jun 1999 | A |
| 5916235 | Guglielmi | Jun 1999 | A |
| 5925060 | Forber | Jul 1999 | A |
| 5928260 | Chin et al. | Jul 1999 | A |
| 5935148 | Villar et al. | Aug 1999 | A |
| 5941249 | Maynard | Aug 1999 | A |
| 5944730 | Nobles et al. | Aug 1999 | A |
| 5944738 | Amplatz et al. | Aug 1999 | A |
| 5951599 | McCrory | Sep 1999 | A |
| 5964797 | Ho | Oct 1999 | A |
| 5976169 | Imran | Nov 1999 | A |
| 5980554 | Lenker et al. | Nov 1999 | A |
| 6022374 | Imran | Feb 2000 | A |
| 6033423 | Ken et al. | Mar 2000 | A |
| 6036720 | Abrams et al. | Mar 2000 | A |
| 6063070 | Eder | May 2000 | A |
| 6063104 | Villar et al. | May 2000 | A |
| 6086577 | Ken et al. | Jul 2000 | A |
| 6090125 | Horton | Jul 2000 | A |
| 6093199 | Brown et al. | Jul 2000 | A |
| 6096021 | Helm et al. | Aug 2000 | A |
| 6123715 | Amplatz | Sep 2000 | A |
| 6139564 | Teoh | Oct 2000 | A |
| 6152144 | Lesh et al. | Nov 2000 | A |
| 6159531 | Dang et al. | Dec 2000 | A |
| 6165193 | Greene, Jr. et al. | Dec 2000 | A |
| 6168615 | Ken et al. | Jan 2001 | B1 |
| 6168622 | Mazzocchi | Jan 2001 | B1 |
| 6238403 | Greene, Jr. et al. | May 2001 | B1 |
| 6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
| 6309367 | Boock | Oct 2001 | B1 |
| 6322576 | Wallace et al. | Nov 2001 | B1 |
| 6344048 | Chin et al. | Feb 2002 | B1 |
| 6346117 | Greenhalgh | Feb 2002 | B1 |
| 6350270 | Roue | Feb 2002 | B1 |
| 6368339 | Amplatz | Apr 2002 | B1 |
| 6371980 | Rudakov et al. | Apr 2002 | B1 |
| 6375668 | Gifford et al. | Apr 2002 | B1 |
| 6383174 | Eder | May 2002 | B1 |
| 6391037 | Greenhalgh | May 2002 | B1 |
| 6428558 | Jones et al. | Aug 2002 | B1 |
| 6447531 | Amplatz | Sep 2002 | B1 |
| 6451050 | Rudakov et al. | Sep 2002 | B1 |
| 6454780 | Wallace | Sep 2002 | B1 |
| 6494884 | Gifford, III et al. | Dec 2002 | B2 |
| 6506204 | Mazzocchi | Jan 2003 | B2 |
| 6511468 | Cragg et al. | Jan 2003 | B1 |
| 6547804 | Porter et al. | Apr 2003 | B2 |
| 6551303 | Van Tassel et al. | Apr 2003 | B1 |
| 6569179 | Teoh et al. | May 2003 | B2 |
| 6579303 | Amplatz | Jun 2003 | B2 |
| 6585748 | Jeffree | Jul 2003 | B1 |
| 6589256 | Forber | Jul 2003 | B2 |
| 6589265 | Palmer et al. | Jul 2003 | B1 |
| 6591472 | Noone et al. | Jul 2003 | B1 |
| 6592605 | Lenker et al. | Jul 2003 | B2 |
| 6599308 | Amplatz | Jul 2003 | B2 |
| 6602261 | Greene, Jr. et al. | Aug 2003 | B2 |
| 6605101 | Schaefer et al. | Aug 2003 | B1 |
| 6605102 | Mazzocchi et al. | Aug 2003 | B1 |
| 6605111 | Bose et al. | Aug 2003 | B2 |
| 6613074 | Mitelberg et al. | Sep 2003 | B1 |
| 6626939 | Burnside et al. | Sep 2003 | B1 |
| 6635068 | Dubrul et al. | Oct 2003 | B1 |
| 6652555 | Vantassel et al. | Nov 2003 | B1 |
| 6652556 | Vantassel et al. | Nov 2003 | B1 |
| 6666882 | Bose et al. | Dec 2003 | B1 |
| 6669717 | Marotta et al. | Dec 2003 | B2 |
| 6669721 | Bose et al. | Dec 2003 | B1 |
| 6682546 | Amplatz | Jan 2004 | B2 |
| 6689150 | VanTassel et al. | Feb 2004 | B1 |
| 6689486 | Ho et al. | Feb 2004 | B2 |
| 6723112 | Ho et al. | Apr 2004 | B2 |
| 6723116 | Taheri | Apr 2004 | B2 |
| 6730108 | Van Tassel et al. | May 2004 | B2 |
| 6746468 | Sepetka et al. | Jun 2004 | B1 |
| 6746890 | Gupta et al. | Jun 2004 | B2 |
| 6780196 | Chin et al. | Aug 2004 | B2 |
| 6802851 | Jones et al. | Oct 2004 | B2 |
| 6811560 | Jones et al. | Nov 2004 | B2 |
| 6855153 | Saadat | Feb 2005 | B2 |
| 6855154 | Abdel-gawwad | Feb 2005 | B2 |
| 6878384 | Cruise et al. | Apr 2005 | B2 |
| 6905503 | Gifford, III et al. | Jun 2005 | B2 |
| 6936055 | Ken et al. | Aug 2005 | B1 |
| 6936058 | Forde et al. | Aug 2005 | B2 |
| 6949113 | Van Tassel et al. | Sep 2005 | B2 |
| 6953473 | Porter | Oct 2005 | B2 |
| 6989019 | Mazzocchi et al. | Jan 2006 | B2 |
| 6991617 | Hektner et al. | Jan 2006 | B2 |
| 6994092 | Van Der Burg et al. | Feb 2006 | B2 |
| 6994717 | Kónya et al. | Feb 2006 | B2 |
| 7011671 | Welch | Mar 2006 | B2 |
| 7014645 | Greene, Jr. et al. | Mar 2006 | B2 |
| 7029487 | Greene, Jr. et al. | Apr 2006 | B2 |
| 7029949 | Farnworth et al. | Apr 2006 | B2 |
| 7070609 | West | Jul 2006 | B2 |
| 7083632 | Avellanet et al. | Aug 2006 | B2 |
| 7098194 | Chenite et al. | Aug 2006 | B2 |
| 7128073 | Van Der Burg et al. | Oct 2006 | B1 |
| 7128736 | Abrams et al. | Oct 2006 | B1 |
| 7153323 | Teoh et al. | Dec 2006 | B1 |
| 7169177 | Obara | Jan 2007 | B2 |
| 7195636 | Avellanet et al. | Mar 2007 | B2 |
| 7229461 | Chin et al. | Jun 2007 | B2 |
| 7232461 | Ramer | Jun 2007 | B2 |
| 7306622 | Jones et al. | Dec 2007 | B2 |
| 7326225 | Ferrera et al. | Feb 2008 | B2 |
| 7331980 | Dubrul et al. | Feb 2008 | B2 |
| 7367986 | Mazzocchi et al. | May 2008 | B2 |
| 7410482 | Murphy et al. | Aug 2008 | B2 |
| 7419503 | Pulnev et al. | Sep 2008 | B2 |
| 7473266 | Glaser | Jan 2009 | B2 |
| 7481821 | Fogarty et al. | Jan 2009 | B2 |
| 7491214 | Greene, Jr. et al. | Feb 2009 | B2 |
| 7569066 | Gerberding et al. | Aug 2009 | B2 |
| 7572288 | Cox | Aug 2009 | B2 |
| 7597704 | Frazier et al. | Oct 2009 | B2 |
| 7601160 | Richter | Oct 2009 | B2 |
| 7608088 | Jones et al. | Oct 2009 | B2 |
| 7695488 | Berenstein et al. | Apr 2010 | B2 |
| 7699056 | Tran et al. | Apr 2010 | B2 |
| 7708754 | Balgobin et al. | May 2010 | B2 |
| 7727189 | Vantassel et al. | Jun 2010 | B2 |
| 7744583 | Seifert et al. | Jun 2010 | B2 |
| 7744652 | Morsi | Jun 2010 | B2 |
| 7879065 | Gesswein et al. | Feb 2011 | B2 |
| 7976527 | Cragg et al. | Jul 2011 | B2 |
| RE42625 | Guglielmi | Aug 2011 | E |
| 7993364 | Morsi | Aug 2011 | B2 |
| RE42758 | Ken et al. | Sep 2011 | E |
| 8012210 | Lin et al. | Sep 2011 | B2 |
| 8043326 | Hancock et al. | Oct 2011 | B2 |
| 8062379 | Morsi | Nov 2011 | B2 |
| 8075585 | Lee et al. | Dec 2011 | B2 |
| 8137293 | Zhou et al. | Mar 2012 | B2 |
| 8142456 | Rosqueta et al. | Mar 2012 | B2 |
| 8153612 | Ben-shalom et al. | Apr 2012 | B2 |
| 8202280 | Richter | Jun 2012 | B2 |
| 8211160 | Garrison et al. | Jul 2012 | B2 |
| 8221445 | Van Tassel et al. | Jul 2012 | B2 |
| 8333783 | Braun et al. | Dec 2012 | B2 |
| 8343167 | Henson | Jan 2013 | B2 |
| 8361104 | Jones et al. | Jan 2013 | B2 |
| 8361138 | Adams | Jan 2013 | B2 |
| 8372062 | Murphy et al. | Feb 2013 | B2 |
| 8398670 | Amplatz et al. | Mar 2013 | B2 |
| 8425541 | Masters et al. | Apr 2013 | B2 |
| 8470013 | Duggal et al. | Jun 2013 | B2 |
| 8530632 | Tijsma et al. | Sep 2013 | B2 |
| 8597320 | Sepetka et al. | Dec 2013 | B2 |
| 8603128 | Greene, Jr. et al. | Dec 2013 | B2 |
| 8653319 | Amery et al. | Feb 2014 | B2 |
| 8690936 | Nguyen et al. | Apr 2014 | B2 |
| 8715317 | Janardhan et al. | May 2014 | B1 |
| 8809301 | Athanasiadis et al. | Aug 2014 | B2 |
| 8834515 | Win et al. | Sep 2014 | B2 |
| 8840867 | Sophie et al. | Sep 2014 | B2 |
| 8906057 | Connor et al. | Dec 2014 | B2 |
| 8974512 | Aboytes et al. | Mar 2015 | B2 |
| 8998947 | Aboytes et al. | Apr 2015 | B2 |
| 9034348 | Ben-shalom et al. | May 2015 | B2 |
| 9192574 | Medina et al. | Nov 2015 | B2 |
| 9192692 | Medina et al. | Nov 2015 | B2 |
| 9211202 | Strother et al. | Dec 2015 | B2 |
| 9301769 | Brady et al. | Apr 2016 | B2 |
| 9314248 | Molaei | Apr 2016 | B2 |
| 9333220 | Tijsma et al. | May 2016 | B2 |
| 9339275 | Trommeter et al. | May 2016 | B2 |
| 9433636 | Tijsma et al. | Sep 2016 | B2 |
| 9486224 | Riina et al. | Nov 2016 | B2 |
| 9555120 | Andersson | Jan 2017 | B2 |
| 9629636 | Fogarty et al. | Apr 2017 | B2 |
| 9655842 | Girdhar et al. | May 2017 | B1 |
| 9681861 | Heisel et al. | Jun 2017 | B2 |
| 9700648 | Hissong et al. | Jul 2017 | B2 |
| 9713475 | Divino et al. | Jul 2017 | B2 |
| 9731043 | Lerouge et al. | Aug 2017 | B2 |
| 9833309 | Levi et al. | Dec 2017 | B2 |
| 9844380 | Furey | Dec 2017 | B2 |
| 9901543 | Chausson et al. | Feb 2018 | B2 |
| 9907684 | Connor et al. | Mar 2018 | B2 |
| 9918718 | Lorenzo | Mar 2018 | B2 |
| 9925210 | Mccarthy et al. | Mar 2018 | B2 |
| 9962146 | Hebert et al. | May 2018 | B2 |
| 10028745 | Morsi | Jul 2018 | B2 |
| 10130372 | Griffin | Nov 2018 | B2 |
| 10517986 | Sherman et al. | Dec 2019 | B2 |
| 10576099 | Li et al. | Mar 2020 | B2 |
| 10632143 | Mccarthy et al. | Apr 2020 | B2 |
| 10932933 | Bardsley et al. | Mar 2021 | B2 |
| 10952740 | Dasnurkar et al. | Mar 2021 | B2 |
| 11076860 | Lorenzo | Aug 2021 | B2 |
| 11134953 | Solaun | Oct 2021 | B2 |
| 11179159 | Cox et al. | Nov 2021 | B2 |
| 11504816 | Nguyen | Nov 2022 | B2 |
| 11679458 | Nguyen et al. | Jun 2023 | B2 |
| 11685007 | Li et al. | Jun 2023 | B2 |
| 11717924 | Nguyen et al. | Aug 2023 | B2 |
| 11826863 | Li et al. | Nov 2023 | B2 |
| 20010000797 | Mazzocchi | May 2001 | A1 |
| 20010001835 | Greene et al. | May 2001 | A1 |
| 20020026210 | Abdel-gawwad | Feb 2002 | A1 |
| 20020042628 | Chin et al. | Apr 2002 | A1 |
| 20020062145 | Rudakov et al. | May 2002 | A1 |
| 20020119177 | Bowman et al. | Aug 2002 | A1 |
| 20020147462 | Mair et al. | Oct 2002 | A1 |
| 20020165572 | Saadat | Nov 2002 | A1 |
| 20020169473 | Sepetka et al. | Nov 2002 | A1 |
| 20020193812 | Patel et al. | Dec 2002 | A1 |
| 20020193813 | Helkowski et al. | Dec 2002 | A1 |
| 20030004533 | Dieck et al. | Jan 2003 | A1 |
| 20030004568 | Ken et al. | Jan 2003 | A1 |
| 20030018294 | Cox | Jan 2003 | A1 |
| 20030028209 | Teoh et al. | Feb 2003 | A1 |
| 20030040772 | Hyodoh et al. | Feb 2003 | A1 |
| 20030055440 | Jones et al. | Mar 2003 | A1 |
| 20030065303 | Wellman et al. | Apr 2003 | A1 |
| 20030093111 | Ken et al. | May 2003 | A1 |
| 20030113478 | Dang et al. | Jun 2003 | A1 |
| 20030114918 | Garrison et al. | Jun 2003 | A1 |
| 20030149490 | Ashman | Aug 2003 | A1 |
| 20030171739 | Murphy et al. | Sep 2003 | A1 |
| 20030187473 | Berenstein et al. | Oct 2003 | A1 |
| 20030195553 | Wallace et al. | Oct 2003 | A1 |
| 20030212419 | West | Nov 2003 | A1 |
| 20040034386 | Fulton et al. | Feb 2004 | A1 |
| 20040044361 | Frazier et al. | Mar 2004 | A1 |
| 20040044391 | Porter | Mar 2004 | A1 |
| 20040064093 | Hektner et al. | Apr 2004 | A1 |
| 20040098027 | Teoh et al. | May 2004 | A1 |
| 20040106945 | Thramann et al. | Jun 2004 | A1 |
| 20040115164 | Pierce et al. | Jun 2004 | A1 |
| 20040122467 | Vantassel et al. | Jun 2004 | A1 |
| 20040138758 | Kronengold et al. | Jul 2004 | A1 |
| 20040161451 | Pierce et al. | Aug 2004 | A1 |
| 20040167597 | Costantino et al. | Aug 2004 | A1 |
| 20040176798 | Foy et al. | Sep 2004 | A1 |
| 20040181253 | Sepetka et al. | Sep 2004 | A1 |
| 20040236344 | Monstadt | Nov 2004 | A1 |
| 20050021077 | Chin et al. | Jan 2005 | A1 |
| 20050038470 | Van Der Burg et al. | Feb 2005 | A1 |
| 20050049625 | Shaya et al. | Mar 2005 | A1 |
| 20050119684 | Guterman et al. | Jun 2005 | A1 |
| 20050131443 | Abdel-gawwad | Jun 2005 | A1 |
| 20050222580 | Gifford et al. | Oct 2005 | A1 |
| 20050267510 | Razack | Dec 2005 | A1 |
| 20050267511 | Marks et al. | Dec 2005 | A1 |
| 20050267527 | Sandoval et al. | Dec 2005 | A1 |
| 20050277978 | Greenhalgh | Dec 2005 | A1 |
| 20050278023 | Zwirkoski | Dec 2005 | A1 |
| 20060028209 | Walker | Feb 2006 | A1 |
| 20060034883 | Dang et al. | Feb 2006 | A1 |
| 20060052816 | Bates et al. | Mar 2006 | A1 |
| 20060064151 | Guterman et al. | Mar 2006 | A1 |
| 20060106421 | Teoh | May 2006 | A1 |
| 20060116709 | Sepetka et al. | Jun 2006 | A1 |
| 20060116712 | Sepetka et al. | Jun 2006 | A1 |
| 20060116713 | Sepetka et al. | Jun 2006 | A1 |
| 20060116714 | Sepetka et al. | Jun 2006 | A1 |
| 20060122548 | Abrams | Jun 2006 | A1 |
| 20060155323 | Porter et al. | Jul 2006 | A1 |
| 20060190070 | Dieck et al. | Aug 2006 | A1 |
| 20060200234 | Hines | Sep 2006 | A1 |
| 20060206140 | Shaolian et al. | Sep 2006 | A1 |
| 20060206198 | Churchwell et al. | Sep 2006 | A1 |
| 20060206199 | Churchwell et al. | Sep 2006 | A1 |
| 20060241686 | Ferrera et al. | Oct 2006 | A1 |
| 20060247680 | Amplatz et al. | Nov 2006 | A1 |
| 20060271162 | Vito et al. | Nov 2006 | A1 |
| 20060276824 | Mitelberg et al. | Dec 2006 | A1 |
| 20060276829 | Balgobin et al. | Dec 2006 | A1 |
| 20060276830 | Balgobin et al. | Dec 2006 | A1 |
| 20070003594 | Brady et al. | Jan 2007 | A1 |
| 20070010850 | Balgobin et al. | Jan 2007 | A1 |
| 20070014831 | Sung et al. | Jan 2007 | A1 |
| 20070083226 | Buiser et al. | Apr 2007 | A1 |
| 20070100426 | Rudakov et al. | May 2007 | A1 |
| 20070135907 | Wilson et al. | Jun 2007 | A1 |
| 20070167876 | Euteneuer et al. | Jul 2007 | A1 |
| 20070167877 | Euteneuer et al. | Jul 2007 | A1 |
| 20070167972 | Euteneuer et al. | Jul 2007 | A1 |
| 20070175536 | Monetti et al. | Aug 2007 | A1 |
| 20070179507 | Shah | Aug 2007 | A1 |
| 20070179520 | West | Aug 2007 | A1 |
| 20070185442 | Euteneuer et al. | Aug 2007 | A1 |
| 20070185443 | Euteneuer et al. | Aug 2007 | A1 |
| 20070185444 | Euteneuer et al. | Aug 2007 | A1 |
| 20070185457 | Euteneuer et al. | Aug 2007 | A1 |
| 20070186933 | Domingo et al. | Aug 2007 | A1 |
| 20070191924 | Rudakov | Aug 2007 | A1 |
| 20070198059 | Patel et al. | Aug 2007 | A1 |
| 20070198075 | Levy | Aug 2007 | A1 |
| 20070219619 | Dieck et al. | Sep 2007 | A1 |
| 20070221230 | Thompson et al. | Sep 2007 | A1 |
| 20070265656 | Amplatz et al. | Nov 2007 | A1 |
| 20070270902 | Slazas et al. | Nov 2007 | A1 |
| 20070276426 | Euteneuer | Nov 2007 | A1 |
| 20070276427 | Euteneuer | Nov 2007 | A1 |
| 20070282373 | Ashby et al. | Dec 2007 | A1 |
| 20070288083 | Hines | Dec 2007 | A1 |
| 20070299461 | Elliott | Dec 2007 | A1 |
| 20080033366 | Matson et al. | Feb 2008 | A1 |
| 20080065145 | Carpenter | Mar 2008 | A1 |
| 20080081763 | Swetlin et al. | Apr 2008 | A1 |
| 20080082176 | Slazas | Apr 2008 | A1 |
| 20080086196 | Truckai et al. | Apr 2008 | A1 |
| 20080109057 | Calabria et al. | May 2008 | A1 |
| 20080114391 | Dieck et al. | May 2008 | A1 |
| 20080114436 | Dieck et al. | May 2008 | A1 |
| 20080119886 | Greenhalgh et al. | May 2008 | A1 |
| 20080125852 | Garrison et al. | May 2008 | A1 |
| 20080132820 | Buckman et al. | Jun 2008 | A1 |
| 20080140177 | Hines | Jun 2008 | A1 |
| 20080195137 | Alleyne et al. | Aug 2008 | A1 |
| 20080200945 | Amplatz et al. | Aug 2008 | A1 |
| 20080200979 | Dieck et al. | Aug 2008 | A1 |
| 20080221554 | Oconnor et al. | Sep 2008 | A1 |
| 20080221600 | Dieck et al. | Sep 2008 | A1 |
| 20080221703 | Que et al. | Sep 2008 | A1 |
| 20080281350 | Sepetka et al. | Nov 2008 | A1 |
| 20080283066 | Delgado et al. | Nov 2008 | A1 |
| 20090018637 | Paul, Jr. et al. | Jan 2009 | A1 |
| 20090024224 | Chen et al. | Jan 2009 | A1 |
| 20090025820 | Adams | Jan 2009 | A1 |
| 20090036877 | Nardone et al. | Feb 2009 | A1 |
| 20090043375 | Rudakov et al. | Feb 2009 | A1 |
| 20090056722 | Swann | Mar 2009 | A1 |
| 20090062899 | Dang et al. | Mar 2009 | A1 |
| 20090076540 | Marks et al. | Mar 2009 | A1 |
| 20090099592 | Buiser et al. | Apr 2009 | A1 |
| 20090112249 | Miles et al. | Apr 2009 | A1 |
| 20090112251 | Qian et al. | Apr 2009 | A1 |
| 20090125119 | Obermiller et al. | May 2009 | A1 |
| 20090148492 | Dave et al. | Jun 2009 | A1 |
| 20090155367 | Neuwirth et al. | Jun 2009 | A1 |
| 20090187214 | Amplatz et al. | Jul 2009 | A1 |
| 20090264978 | Dieck et al. | Oct 2009 | A1 |
| 20090270974 | Berez et al. | Oct 2009 | A1 |
| 20090275974 | Marchand et al. | Nov 2009 | A1 |
| 20090287291 | Becking et al. | Nov 2009 | A1 |
| 20090287292 | Becking et al. | Nov 2009 | A1 |
| 20090287294 | Rosqueta et al. | Nov 2009 | A1 |
| 20090287297 | Cox | Nov 2009 | A1 |
| 20090297582 | Meyer et al. | Dec 2009 | A1 |
| 20090306702 | Miloslavski et al. | Dec 2009 | A1 |
| 20090306706 | Osypka | Dec 2009 | A1 |
| 20090318892 | Aboytes et al. | Dec 2009 | A1 |
| 20090318941 | Sepetka et al. | Dec 2009 | A1 |
| 20090319023 | Hildebrand et al. | Dec 2009 | A1 |
| 20100021545 | Chaput et al. | Jan 2010 | A1 |
| 20100023048 | Mach | Jan 2010 | A1 |
| 20100030200 | Strauss et al. | Feb 2010 | A1 |
| 20100036410 | Krolik et al. | Feb 2010 | A1 |
| 20100106178 | Obermiller et al. | Apr 2010 | A1 |
| 20100121350 | Mirigian | May 2010 | A1 |
| 20100131002 | Connor et al. | May 2010 | A1 |
| 20100139465 | Christian et al. | Jun 2010 | A1 |
| 20100144895 | Porter | Jun 2010 | A1 |
| 20100160949 | Takuma | Jun 2010 | A1 |
| 20100174269 | Tompkins et al. | Jul 2010 | A1 |
| 20100184720 | Gavard et al. | Jul 2010 | A1 |
| 20100185271 | Zhang | Jul 2010 | A1 |
| 20100228184 | Mavani et al. | Sep 2010 | A1 |
| 20100249830 | Nelson | Sep 2010 | A1 |
| 20100256527 | Lippert et al. | Oct 2010 | A1 |
| 20100256528 | Lippert et al. | Oct 2010 | A1 |
| 20100256601 | Lippert et al. | Oct 2010 | A1 |
| 20100256602 | Lippert et al. | Oct 2010 | A1 |
| 20100256603 | Lippert et al. | Oct 2010 | A1 |
| 20100256604 | Lippert et al. | Oct 2010 | A1 |
| 20100256605 | Lippert et al. | Oct 2010 | A1 |
| 20100256606 | Lippert et al. | Oct 2010 | A1 |
| 20100262014 | Huang | Oct 2010 | A1 |
| 20100268201 | Tieu et al. | Oct 2010 | A1 |
| 20100274276 | Chow et al. | Oct 2010 | A1 |
| 20100298791 | Jones et al. | Nov 2010 | A1 |
| 20100312061 | Hess et al. | Dec 2010 | A1 |
| 20110022149 | Cox et al. | Jan 2011 | A1 |
| 20110046658 | Connor et al. | Feb 2011 | A1 |
| 20110077620 | Debeer | Mar 2011 | A1 |
| 20110125110 | Cotton | May 2011 | A1 |
| 20110137332 | Sepetka et al. | Jun 2011 | A1 |
| 20110137405 | Wilson et al. | Jun 2011 | A1 |
| 20110144669 | Becking et al. | Jun 2011 | A1 |
| 20110152993 | Marchand et al. | Jun 2011 | A1 |
| 20110166588 | Connor et al. | Jul 2011 | A1 |
| 20110196415 | Ujiie et al. | Aug 2011 | A1 |
| 20110202085 | Loganathan et al. | Aug 2011 | A1 |
| 20110208227 | Becking | Aug 2011 | A1 |
| 20110224776 | Sepetka et al. | Sep 2011 | A1 |
| 20110238041 | Lim et al. | Sep 2011 | A1 |
| 20110245862 | Dieck et al. | Oct 2011 | A1 |
| 20110251699 | Ladet | Oct 2011 | A1 |
| 20110265943 | Rosqueta et al. | Nov 2011 | A1 |
| 20110319926 | Becking et al. | Dec 2011 | A1 |
| 20120010644 | Sideris et al. | Jan 2012 | A1 |
| 20120022572 | Braun et al. | Jan 2012 | A1 |
| 20120041472 | Tan et al. | Feb 2012 | A1 |
| 20120101510 | Lenker et al. | Apr 2012 | A1 |
| 20120116350 | Strauss et al. | May 2012 | A1 |
| 20120123510 | Liungman | May 2012 | A1 |
| 20120143237 | Cam et al. | Jun 2012 | A1 |
| 20120143243 | Hill et al. | Jun 2012 | A1 |
| 20120143301 | Maslanka et al. | Jun 2012 | A1 |
| 20120165919 | Cox et al. | Jun 2012 | A1 |
| 20120197283 | Marchand et al. | Aug 2012 | A1 |
| 20120239074 | Aboytes et al. | Sep 2012 | A1 |
| 20120283768 | Cox et al. | Nov 2012 | A1 |
| 20120283769 | Cruise et al. | Nov 2012 | A1 |
| 20120310269 | Fearnot et al. | Dec 2012 | A1 |
| 20120316598 | Becking et al. | Dec 2012 | A1 |
| 20120316632 | Gao | Dec 2012 | A1 |
| 20120323271 | Obermiller et al. | Dec 2012 | A1 |
| 20120330341 | Becking et al. | Dec 2012 | A1 |
| 20120330347 | Becking et al. | Dec 2012 | A1 |
| 20120330348 | Strauss et al. | Dec 2012 | A1 |
| 20130066357 | Aboytes et al. | Mar 2013 | A1 |
| 20130066360 | Becking et al. | Mar 2013 | A1 |
| 20130073026 | Russo et al. | Mar 2013 | A1 |
| 20130085522 | Becking et al. | Apr 2013 | A1 |
| 20130116722 | Aboytes et al. | May 2013 | A1 |
| 20130138136 | Beckham et al. | May 2013 | A1 |
| 20130211495 | Halden et al. | Aug 2013 | A1 |
| 20130244972 | Ben-Shalom et al. | Sep 2013 | A1 |
| 20130274866 | Cox et al. | Oct 2013 | A1 |
| 20140012307 | Franano et al. | Jan 2014 | A1 |
| 20140017210 | Laurencin et al. | Jan 2014 | A1 |
| 20140039542 | Trommeter et al. | Feb 2014 | A1 |
| 20140058420 | Hannes et al. | Feb 2014 | A1 |
| 20140135810 | Divino et al. | May 2014 | A1 |
| 20140135811 | Divino et al. | May 2014 | A1 |
| 20140135812 | Divino et al. | May 2014 | A1 |
| 20140200607 | Sepetka et al. | Jul 2014 | A1 |
| 20140215792 | Leopold et al. | Aug 2014 | A1 |
| 20140257360 | Keillor | Sep 2014 | A1 |
| 20140257361 | Prom | Sep 2014 | A1 |
| 20140257374 | Heisel et al. | Sep 2014 | A1 |
| 20140316012 | Freyman et al. | Oct 2014 | A1 |
| 20140371734 | Truckai | Dec 2014 | A1 |
| 20140377187 | Lerouge et al. | Dec 2014 | A1 |
| 20150005808 | Chouinard et al. | Jan 2015 | A1 |
| 20150133989 | Lubock et al. | May 2015 | A1 |
| 20150216684 | Enzmann et al. | Aug 2015 | A1 |
| 20150250628 | Monstadt et al. | Sep 2015 | A1 |
| 20150272589 | Lorenzo | Oct 2015 | A1 |
| 20150272590 | Aboytes et al. | Oct 2015 | A1 |
| 20150313605 | Griffin | Nov 2015 | A1 |
| 20150313737 | Tippett et al. | Nov 2015 | A1 |
| 20150327843 | Garrison | Nov 2015 | A1 |
| 20150335333 | Jones et al. | Nov 2015 | A1 |
| 20150342613 | Aboytes et al. | Dec 2015 | A1 |
| 20150343181 | Bradway et al. | Dec 2015 | A1 |
| 20160022445 | Ruvalcaba et al. | Jan 2016 | A1 |
| 20160030050 | Franano et al. | Feb 2016 | A1 |
| 20160066921 | Seifert et al. | Mar 2016 | A1 |
| 20160106437 | Van Der Burg et al. | Apr 2016 | A1 |
| 20160128699 | Hadley et al. | May 2016 | A1 |
| 20160135984 | Rudakov et al. | May 2016 | A1 |
| 20160206320 | Connor | Jul 2016 | A1 |
| 20160206321 | Connor | Jul 2016 | A1 |
| 20160249935 | Hewitt et al. | Sep 2016 | A1 |
| 20160256170 | Busold et al. | Sep 2016 | A1 |
| 20160331381 | Ma | Nov 2016 | A1 |
| 20170105739 | Dias et al. | Apr 2017 | A1 |
| 20170150971 | Hines | Jun 2017 | A1 |
| 20170156734 | Griffin | Jun 2017 | A1 |
| 20170156903 | Shobayashi | Jun 2017 | A1 |
| 20170189035 | Porter | Jul 2017 | A1 |
| 20170224350 | Shimizu et al. | Aug 2017 | A1 |
| 20170224355 | Bowman et al. | Aug 2017 | A1 |
| 20170266023 | Thomas | Sep 2017 | A1 |
| 20170296466 | Girdhar et al. | Oct 2017 | A1 |
| 20170312364 | Bossy et al. | Nov 2017 | A1 |
| 20170340333 | Badruddin et al. | Nov 2017 | A1 |
| 20170354421 | Maguire et al. | Dec 2017 | A1 |
| 20170367708 | Mayer et al. | Dec 2017 | A1 |
| 20170367713 | Greene, Jr. et al. | Dec 2017 | A1 |
| 20180049859 | Stoppenhagen et al. | Feb 2018 | A1 |
| 20180070955 | Greene, Jr. et al. | Mar 2018 | A1 |
| 20180110797 | Li et al. | Apr 2018 | A1 |
| 20180125686 | Lu | May 2018 | A1 |
| 20180132856 | Wierzbicki et al. | May 2018 | A1 |
| 20180140305 | Connor | May 2018 | A1 |
| 20180161185 | Kresslein et al. | Jun 2018 | A1 |
| 20180193025 | Walzman | Jul 2018 | A1 |
| 20180193026 | Yang et al. | Jul 2018 | A1 |
| 20180206852 | Moeller | Jul 2018 | A1 |
| 20180242979 | Lorenzo | Aug 2018 | A1 |
| 20180256171 | Chow et al. | Sep 2018 | A1 |
| 20180317932 | H'doubler | Nov 2018 | A1 |
| 20190008522 | Lorenzo | Jan 2019 | A1 |
| 20190009057 | Li et al. | Jan 2019 | A1 |
| 20190053807 | Tassoni et al. | Feb 2019 | A1 |
| 20190053811 | Garza et al. | Feb 2019 | A1 |
| 20190223876 | Badruddin et al. | Jul 2019 | A1 |
| 20190223881 | Hewitt et al. | Jul 2019 | A1 |
| 20190282242 | Divino et al. | Sep 2019 | A1 |
| 20190343532 | Divino et al. | Nov 2019 | A1 |
| 20190351107 | Sawhney et al. | Nov 2019 | A1 |
| 20200060965 | Supper | Feb 2020 | A1 |
| 20200061099 | Li et al. | Feb 2020 | A1 |
| 20200113576 | Gorochow et al. | Apr 2020 | A1 |
| 20200138448 | Dasnurkar et al. | May 2020 | A1 |
| 20200268392 | Choi et al. | Aug 2020 | A1 |
| 20200360419 | Mccarthy et al. | Nov 2020 | A1 |
| 20210022743 | Delaney, Jr. et al. | Jan 2021 | A1 |
| 20210128160 | Li et al. | May 2021 | A1 |
| 20210128161 | Nageswaran et al. | May 2021 | A1 |
| 20210128162 | Rhee et al. | May 2021 | A1 |
| 20210128165 | Pulugurtha et al. | May 2021 | A1 |
| 20210128167 | Patel et al. | May 2021 | A1 |
| 20210128168 | Nguyen et al. | May 2021 | A1 |
| 20210128169 | Li et al. | May 2021 | A1 |
| 20210129275 | Nguyen et al. | May 2021 | A1 |
| 20210153872 | Nguyen et al. | May 2021 | A1 |
| 20210161643 | Totten et al. | Jun 2021 | A1 |
| 20210196284 | Gorochow et al. | Jul 2021 | A1 |
| 20210212698 | Connor | Jul 2021 | A1 |
| 20220008082 | Connor | Jan 2022 | A1 |
| 20220304696 | Rhee et al. | Sep 2022 | A2 |
| 20230294223 | Li et al. | Sep 2023 | A1 |
| 20230311254 | Nguyen et al. | Oct 2023 | A1 |
| 20230373040 | Nguyen et al. | Nov 2023 | A1 |
| 20240050099 | Pecor et al. | Feb 2024 | A1 |
| 20240075565 | Li et al. | Mar 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 3031482 | Aug 2017 | CA |
| 101460102 | Jun 2009 | CN |
| 102083493 | Jun 2011 | CN |
| 102202585 | Sep 2011 | CN |
| 202313544 | Jul 2012 | CN |
| 102740799 | Oct 2012 | CN |
| 105105812 | Dec 2015 | CN |
| 105209075 | Dec 2015 | CN |
| 102011102933 | Dec 2012 | DE |
| 0717969 | Jun 1996 | EP |
| 1188414 | Mar 2002 | EP |
| 1813213 | Aug 2007 | EP |
| 2208483 | Jul 2010 | EP |
| 1448607 | Jan 2011 | EP |
| 2566454 | Mar 2014 | EP |
| 2468348 | Oct 2016 | EP |
| 2121026 | Jun 2017 | EP |
| 2005261951 | Sep 2005 | JP |
| 2008521492 | Jun 2008 | JP |
| WO 9406502 | Mar 1994 | WO |
| WO 9905977 | Feb 1999 | WO |
| WO 03011151 | Feb 2003 | WO |
| WO 2006034149 | Mar 2006 | WO |
| WO 2007006139 | Jan 2007 | WO |
| WO 2007079402 | Jul 2007 | WO |
| WO 2007121405 | Oct 2007 | WO |
| WO 2008074027 | Jun 2008 | WO |
| WO 2009014528 | Jan 2009 | WO |
| WO 2009134337 | Nov 2009 | WO |
| WO 2010009019 | Jan 2010 | WO |
| WO 2010027363 | Mar 2010 | WO |
| WO 2010028300 | Mar 2010 | WO |
| WO 2010077599 | Jul 2010 | WO |
| WO 2011066962 | Jun 2011 | WO |
| WO 2011095966 | Aug 2011 | WO |
| WO 2012034135 | Mar 2012 | WO |
| WO 2013112944 | Aug 2013 | WO |
| WO 2013138615 | Sep 2013 | WO |
| WO 2013138615 | Sep 2014 | WO |
| WO 2014169708 | Oct 2014 | WO |
| WO 2015160721 | Oct 2015 | WO |
| WO 2015166013 | Nov 2015 | WO |
| WO 2016098057 | Jun 2016 | WO |
| WO 2017074411 | May 2017 | WO |
| WO 2018050262 | Mar 2018 | WO |
| WO 2018051187 | Mar 2018 | WO |
| WO 2019038293 | Feb 2019 | WO |
| WO 2020162764 | Aug 2020 | WO |
| WO 2020236917 | Nov 2020 | WO |
| WO 2020262817 | Dec 2020 | WO |
| WO 2021046389 | Mar 2021 | WO |
| Entry |
|---|
| International Search Report and Written Opinion mailed Aug. 9, 2022; International Application No. PCT/US2022/071166; 10 pages. |
| International Search Report and Written Opinion mailed Feb. 17, 2021, International Application No. PCT/US20/70741, 6 pages. |
| International Search Report and Written Opinion mailed Feb. 23, 2021, International Application No. PCT/US20/70743, 14 pages. |
| Medtronic ENT. (2021). Discover Novapak: Beyond Structural Stability [Brochure]. Medtronic. |
| International Search Report and Written Opinion mailed Apr. 13, 2021, International Application No. PCT/US20/70742,18 pages. |
| Barnett, et al., “Assessment of EmboGel—A Selectively Dissolvable Radiopaque Hydrogel for Embolic Applications”, J Vasc Interv Radiol 2011; vol. 22, No. 2, Feb. 2011, pp. 203-211. |
| Berenstein, et al., “Treatment of Experimental Aneurysms With an Embolic-Containing Device and Liquid Embolic Agent: Feasibility and Angiographic and Histological Results”, Neurosurgery, vol. 64, No. 2, Feb. 2009, pp. 367-373. |
| Brennecka, et al., “In vivo embolization of lateral wall aneurysms in canines using the liquid-to-solid gelling PPODA-QT polymer system: 6-month pilot study”, Laboratory investigation, J Neurosurg, vol. 119,, Jul. 2013, pp. 228-238. |
| Coutu, Jean-Michel, et al., “A new radiopaque embolizing agent for the treatment of endoleaks after endovascular repair: Influence of contrast agent on chitosan thermogel properties”, Journal of Biomedical Materials Research Part B: Applied Biomaterials, 101B(1), 153-161. https://doi.org/10.1002/jbm.b.32828. |
| Jalani, et al., “Tough, In-Situ Thermogelling, Injectable Hydrogels for Biomedical Applications”, Macromolecular Bioscience, 2014, 8 Pages. |
| Murayama, et al., “Endovascular Treatment of Experimental Aneurysms by Use of a Combination of Liquid Embolic Agents and Protective Devices”, Experimental Aneurysms, AJNR Am J Neuroradiol, vol. 21, Oct. 2000, pp. 1726-1735. |
| Ning, et al., “Experimental study of temperature-sensitive chitosan/β-glycerophosphate embolic material in embolizing the basicranial rete mirabile in swines”, Experimental and Therapeutic Medicine, vol. 10, Feb. 19, 2015, pp. 316-322. |
| Shive, Matthew S., et al., “BST-Cargel® treatment maintains cartilage repair superiority over microfracture at 5 years in a multicenter randomized controlled trial.”, CARTILAGE, 6(2), 62-72. https://doi.org/10.1177/1947603514562064. |
| Supper, Stephanie, et al., “Chitosan/glucose 1-phosphate as new stable in situ forming depot system for controlled drug delivery”, European Journal of Pharmaceutics and Biopharmaceutics, 88(2), 361-373. https://doi.org/10.1016/j.ejpb.2014.05.015. |
| Supper, Stephanie, et al., “Rheological Study of Chitosan/Polyol-phosphate Systems: Influence of the Polyol Part on the Thermo-Induced Gelation Mechanism”, Langmuir, 29(32), 10229-10237. https://doi.org/10.1021/la401993q. |
| Wang, et al., “In Vivo Assessment of Chitosan/β-Glycerophosphate as a New Liquid Embolic Agent”, Interventional Neuroradiology, vol. 17, 2011, pp. 87-92. |
| Zhen, et al., “Embolization of aneurysm by chitosan-glycerophosphate-fibroblast tissue hydrogel, a tissue engineering material: experiment with rabbits”, Natl Med J China, vol. 89, No. 11, Mar. 24, 2009, pp. 727-731. |
| Number | Date | Country | |
|---|---|---|---|
| 20230023511 A1 | Jan 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62930487 | Nov 2019 | US | |
| 62930324 | Nov 2019 | US | |
| 62930357 | Nov 2019 | US | |
| 62930333 | Nov 2019 | US | |
| 62930421 | Nov 2019 | US | |
| 62930303 | Nov 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16949566 | Nov 2020 | US |
| Child | 17938143 | US |
